Lytix Biopharma AS: Notice of Annual General Meeting on 29 April 2025

10 Apr 2025 07:10 CEST

Oslo, 10 April 2024, the Board of Directors hereby calls for the Annual General
Meeting of Lytix Biopharma AS (the "Company") in Sandakerveien 130, 0484 Oslo,
Norway at 13:00 Hours (CEST) on 29 April 2025.

All documents regarding the Annual General Meeting are available at the
Company's website: www.lytixbiopharma.com.

For further information, please contact:

Gjest Breistein, CFO
E-mail: gjest.breistein@lytixbiopharma.com
Phone: +47 952 60 512

About Lytix
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly novel technology based on world leading research in host-defense
peptide-derived molecules. Lytix Biopharma’s lead product, LTX-315, is a
first-in-class oncolytic molecule representing a new principle to boost
anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work
in many different cancer indications and treatment settings, both as mono- and
combination therapy.

More information:
Access the news on Oslo Bors NewsWeb site

643371_Lytix - Notice of Annual General Meeting 2025 - Final.pdf
643371_Stock Exchange Notice - Notice AGM 2025 - Lytix Biopharma AS.pdf